362 related articles for article (PubMed ID: 23836560)
1. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.
Cramer-Morales K; Nieborowska-Skorska M; Scheibner K; Padget M; Irvine DA; Sliwinski T; Haas K; Lee J; Geng H; Roy D; Slupianek A; Rassool FV; Wasik MA; Childers W; Copland M; Müschen M; Civin CI; Skorski T
Blood; 2013 Aug; 122(7):1293-304. PubMed ID: 23836560
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.
Sullivan-Reed K; Bolton-Gillespie E; Dasgupta Y; Langer S; Siciliano M; Nieborowska-Skorska M; Hanamshet K; Belyaeva EA; Bernhardy AJ; Lee J; Moore M; Zhao H; Valent P; Matlawska-Wasowska K; Müschen M; Bhatia S; Bhatia R; Johnson N; Wasik MA; Mazin AV; Skorski T
Cell Rep; 2018 Jun; 23(11):3127-3136. PubMed ID: 29898385
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous Targeting of DNA Polymerase Theta and PARP1 or RAD52 Triggers Dual Synthetic Lethality in Homologous Recombination-Deficient Leukemia Cells.
Sullivan-Reed K; Toma MM; Drzewiecka M; Nieborowska-Skorska M; Nejati R; Karami A; Wasik MA; Sliwinski T; Skorski T
Mol Cancer Res; 2023 Oct; 21(10):1017-1022. PubMed ID: 37358557
[TBL] [Abstract][Full Text] [Related]
4. RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination.
Lok BH; Carley AC; Tchang B; Powell SN
Oncogene; 2013 Jul; 32(30):3552-8. PubMed ID: 22964643
[TBL] [Abstract][Full Text] [Related]
5. The function of RAD52 N-terminal domain is essential for viability of BRCA-deficient cells.
Hanamshet K; Mazin AV
Nucleic Acids Res; 2020 Dec; 48(22):12778-12791. PubMed ID: 33275133
[TBL] [Abstract][Full Text] [Related]
6. Targeting HR Repair as a Synthetic Lethal Approach to Increase DNA Damage Sensitivity by a RAD52 Inhibitor in BRCA2-Deficient Cancer Cells.
Tseng WC; Chen CY; Chern CY; Wang CA; Lee WC; Chi YC; Cheng SF; Kuo YT; Chiu YC; Tseng ST; Lin PY; Liou SJ; Li YC; Chen CC
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922657
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement.
Lok BH; Powell SN
Clin Cancer Res; 2012 Dec; 18(23):6400-6. PubMed ID: 23071261
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
9. The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.
Hromas R; Kim HS; Sidhu G; Williamson E; Jaiswal A; Totterdale TA; Nole J; Lee SH; Nickoloff JA; Kong KY
Breast Cancer Res; 2017 Nov; 19(1):122. PubMed ID: 29145865
[TBL] [Abstract][Full Text] [Related]
10. RAD52 aptamer regulates DNA damage repair and STAT3 in BRCA1/BRCA2‑deficient human acute myeloid leukemia.
Xu Y; Lin Y; Luo Y; Yang Y; Long B; Fang Z; Liu L; Zhang J; Zhang X
Oncol Rep; 2020 Oct; 44(4):1455-1466. PubMed ID: 32945515
[TBL] [Abstract][Full Text] [Related]
11. Rad52 inactivation is synthetically lethal with BRCA2 deficiency.
Feng Z; Scott SP; Bussen W; Sharma GG; Guo G; Pandita TK; Powell SN
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):686-91. PubMed ID: 21148102
[TBL] [Abstract][Full Text] [Related]
12. Recovery of deficient homologous recombination in Brca2-depleted mouse cells by wild-type Rad51 expression.
Lee SA; Roques C; Magwood AC; Masson JY; Baker MD
DNA Repair (Amst); 2009 Feb; 8(2):170-81. PubMed ID: 18992372
[TBL] [Abstract][Full Text] [Related]
13. Non-Recombinogenic Functions of Rad51, BRCA2, and Rad52 in DNA Damage Tolerance.
Prado F
Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680945
[TBL] [Abstract][Full Text] [Related]
14. Small-Molecule Disruption of RAD52 Rings as a Mechanism for Precision Medicine in BRCA-Deficient Cancers.
Chandramouly G; McDevitt S; Sullivan K; Kent T; Luz A; Glickman JF; Andrake M; Skorski T; Pomerantz RT
Chem Biol; 2015 Nov; 22(11):1491-1504. PubMed ID: 26548611
[TBL] [Abstract][Full Text] [Related]
15. Pan-cancer analysis of co-occurring mutations in RAD52 and the BRCA1-BRCA2-PALB2 axis in human cancers.
Hamid AB; Frank LE; Bouley RA; Petreaca RC
PLoS One; 2022; 17(9):e0273736. PubMed ID: 36107942
[TBL] [Abstract][Full Text] [Related]
16. ROS-induced R loops trigger a transcription-coupled but BRCA1/2-independent homologous recombination pathway through CSB.
Teng Y; Yadav T; Duan M; Tan J; Xiang Y; Gao B; Xu J; Liang Z; Liu Y; Nakajima S; Shi Y; Levine AS; Zou L; Lan L
Nat Commun; 2018 Oct; 9(1):4115. PubMed ID: 30297739
[TBL] [Abstract][Full Text] [Related]
17. Spatiotemporal dynamics of homologous recombination repair at single collapsed replication forks.
Whelan DR; Lee WTC; Yin Y; Ofri DM; Bermudez-Hernandez K; Keegan S; Fenyo D; Rothenberg E
Nat Commun; 2018 Sep; 9(1):3882. PubMed ID: 30250272
[TBL] [Abstract][Full Text] [Related]
18. A moving target for drug discovery: Structure activity relationship and many genome (de)stabilizing functions of the RAD52 protein.
Bhat DS; Spies MA; Spies M
DNA Repair (Amst); 2022 Dec; 120():103421. PubMed ID: 36327799
[TBL] [Abstract][Full Text] [Related]
19. Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors.
Huang F; Goyal N; Sullivan K; Hanamshet K; Patel M; Mazina OM; Wang CX; An WF; Spoonamore J; Metkar S; Emmitte KA; Cocklin S; Skorski T; Mazin AV
Nucleic Acids Res; 2016 May; 44(9):4189-99. PubMed ID: 26873923
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
Clark CC; Weitzel JN; O'Connor TR
Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
